Companies › Mabwell (Shanghai) Bioscience
13 active drug programs in 37 registered trials: 19 Phase 2, 14 Phase 1, 4 Phase 3; Oncology, Genitourinary, Other, Hematology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 9MW2821 nectin-4 antibody-drug conjugate with MMAE payload | NECTIN4 | Phase 3 | Advanced Urothelial Carcinoma; Urothelial Carcinoma; Cervical Cancer; Triple-Negative Breast Cancer | Dec 2026 |
| Toripalimab (JS001) Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Urothelial Carcinoma; Advanced Urothelial Carcinoma | Dec 2026 |
| 9MW3811 anti-IL-11 monoclonal antibody | IL11 | Phase 2 | Scar | Dec 2026 |
| PD-1 inhibitor PD-1 inhibitor | PDCD1 | Phase 2 | Triple-Negative Breast Cancer | Jul 2027 |
| 9MW1911 | – | Phase 2 | Chronic Obstructive Pulmonary Disease COPD; Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Dec 2027 |
| 9MW2921 | – | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| bulumtatug fuvedotin anti-TROP2 antibody-drug conjugate | TROP2 | Phase 1 | Triple Negative Breast Cancer | May 2027 |
| 7MW4911 | – | Phase 1 | GI Cancers; Solid Tumors | Jul 2027 |
| 7MW3711 | – | Phase 1 | Solid Tumor | Dec 2027 |
| JS207 | – | Phase 1 | Solid Tumor; Advanced Colorectal Cancer; NSCLC; Advanced Malignant Solid Tumors … | Dec 2027 |
| 6MW5311 bispecific T cell engager antibody with bivalent binding to LILRB4 on tumor cells and mono | LILRB4, CD3E | Phase 1 | AML | Dec 2029 |
| 9MW3011 | – | Phase 1 | Polycythemia Vera; Beta-Thalassemia | – |
| 9MW4113 injection IL-4 receptor antagonist monoclonal antibody | – | Phase 1 | Healthy Participants | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06752746 | 9MW3011 | Phase 1 | Polycythemia Vera | Oncology | Aug 2025 |
| NCT06175351 | 9MW1911 | Phase 1 | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Respiratory | Sep 2025 |
| NCT07791342 | 9MW4113 injection | Phase 1 | Healthy Participants | Other | Jul 2026 |
| NCT06772766 | 9MW3011 | Phase 1 | Beta-Thalassemia | Hematology | Oct 2026 |
| NCT06885385 | JS207 | Phase 2 | Advanced Colorectal Cancer | Oncology | Nov 2026 |
| NCT07576608 | 9MW3811 | Phase 2 | Scar | Other | Dec 2026 |
| NCT06022250 | JS207 | Phase 1 | Advanced Malignant Tumor | Oncology | Dec 2026 |
| NCT05990452 | 9MW2921 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT06079112 | 9MW2821 | Phase 1 | Advanced Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT06079112 | Toripalimab (JS001) | Phase 1 | Advanced Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT06944470 | JS207 | Phase 2 | NSCLC | Oncology | Apr 2027 |
| NCT06908928 | bulumtatug fuvedotin | Phase 1 | Triple Negative Breast Cancer | Oncology | May 2027 |
| NCT06823427 | 9MW2821 | Phase 2 | Urothelial Carcinoma | Genitourinary | Jun 2027 |
| NCT06823427 | Toripalimab (JS001) | Phase 2 | Urothelial Carcinoma | Genitourinary | Jun 2027 |
| NCT06196736 | 9MW2821 | Phase 3 | Advanced Urothelial Carcinoma | Oncology | Jul 2027 |
| NCT06492005 | 9MW2821 | Phase 2 | Triple-Negative Breast Cancer | Oncology | Jul 2027 |
| NCT06492005 | PD-1 inhibitor | Phase 2 | Triple-Negative Breast Cancer | Oncology | Jul 2027 |
| NCT07216560 | 7MW4911 | Phase 1 | GI Cancers | Oncology | Jul 2027 |
| NCT07265622 | 7MW4911 | Phase 1 | Solid Tumors | Oncology | Jul 2027 |
| NCT06592326 | 9MW2821 | Phase 3 | Urothelial Carcinoma | Oncology | Sep 2027 |
| NCT06592326 | Toripalimab (JS001) | Phase 3 | Urothelial Carcinoma | Oncology | Sep 2027 |
| NCT07480733 | JS207 | Phase 2 | Advanced Malignant Solid Tumors | Oncology | Nov 2027 |
| NCT07309276 | JS207 | Phase 2 | Advanced Lung Cancer | Oncology | Nov 2027 |
| NCT06692166 | 9MW2821 | Phase 3 | Cervical Cancer | Oncology | Dec 2027 |
| NCT07292714 | 9MW1911 | Phase 2 | Chronic Obstructive Pulmonary Disease COPD | Respiratory | Dec 2027 |
| NCT07503756 | JS207 | Phase 2 | Metastatic Colorectal Cancer | Oncology | Dec 2027 |
| NCT07314723 | 9MW2821 | Phase 2 | Urothelial Carcinoma | Oncology | Dec 2027 |
| NCT07466160 | 7MW3711 | Phase 1 | Solid Tumor | Oncology | Dec 2027 |
| NCT07466160 | JS207 | Phase 1 | Solid Tumor | Oncology | Dec 2027 |
| NCT06969027 | JS207 | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT06954467 | JS207 | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2027 |
| NCT07690787 | JS207 | Phase 2 | Recurrent/ Metastatic NPC | Oncology | Dec 2027 |
| NCT07314723 | Toripalimab (JS001) | Phase 2 | Urothelial Carcinoma | Oncology | Dec 2027 |
| NCT07045311 | JS207 | Phase 2 | Triple-negative Breast Cancer | Oncology | Mar 2028 |
| NCT07045311 | JS207 | Phase 2 | Triple-negative Breast Cancer | Oncology | Mar 2028 |
| NCT06868836 | JS207 | Phase 2 | Non-squamous Non-small Cell Lung Cancer | Oncology | Apr 2028 |
| NCT07914556 | 6MW5311 | Phase 1 | AML | Oncology | Dec 2029 |
Bio-Thera Solutions Akeso Sichuan Baili Pharmaceutical Shenyang Sunshine Pharmaceutical Jiangsu Simcere Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.